STOCK TITAN
  1. Home
  2. News
  3. CYRX

CryoPort Inc - CYRX STOCK NEWS

Welcome to our dedicated news page for CryoPort (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on CryoPort.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CryoPort's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CryoPort's position in the market.

News
Cryoport Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Cryoport, Inc. reported FY 2023 revenue of $233.3 million, meeting guidance. Commercial Cell & Gene Therapy revenue rose 33%, BioStorage/BioServices revenue increased 45%. The company supported a record 675 global clinical trials. Strategic investments were made to drive growth, including acquisitions and collaborations. Financially, revenue decreased by 2% YoY. Despite challenges, Cryoport aims for strong growth in the Cell & Gene therapy sector in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.9%
Tags
earnings
-
News
Cryoport to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
Rhea-AI Summary
Cryoport, Inc. (CYRX) will release financial results for Q4 and full year 2023 on March 12, 2024, followed by a conference call addressing investors' questions. The company aims to provide insights into its financial and operational performance through the 'Cryoport Fourth Quarter and Full Year 2023 in Review' document.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
conferences earnings
-
News
Cryoport and NIPPON EXPRESS HOLDINGS Form Global Strategic Partnership for Temperature-Controlled Supply Chain Services
Rhea-AI Summary
Cryoport Inc. (CYRX) and Nippon Express Holdings, Inc. have announced a strategic partnership to provide temperature-controlled supply chain services for the life sciences industry on a global basis. This partnership aims to design and implement comprehensive supply chain solutions to support each other's business efforts, covering globally. The collaboration brings together Nippon Express' industry-leading global logistics with Cryoport Systems' fully integrated system, processes, and equipment, including its shipping packages, data solutions, biostorage, and bioservices, to provide complete cell and gene therapy support services from upstream biomaterial collection to final delivery for dosing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
partnership
News
Cryoport's CRYOPDP Expands U.S. Footprint with Acquisition of Bluebird Express
Rhea-AI Summary
Cryoport, Inc. (NASDAQ: CYRX) announced the acquisition of Bluebird Express, LLC, a provider of time-sensitive domestic and international transportation services. The acquisition aims to strengthen CRYOPDP's U.S. logistics operations and expand its global supply chain network. Bluebird Express will merge into CRYOPDP's global network, enhancing its capabilities in the critical life sciences market. The addition of Bluebird Express will increase Cryoport's U.S. footprint and further the expansion of its global infrastructure and competencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
acquisition
-
News
Cryoport Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Cryoport, Inc. (NASDAQ: CYRX) announced a 54% year-over-year growth in commercial Cell and Gene Therapy revenue for Q3 2023, totaling $56.2 million. The company also affirmed its full year 2023 revenue guidance of $233 - $243 million. Cryoport's CEO, Jerrell Shelton, highlighted notable partnerships and acquisitions, emphasizing the company's leading market position and long-term growth prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.03%
Tags
earnings
-
News
Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition
Rhea-AI Summary
Cryoport, Inc. has announced the acquisition of Tec4med Lifescience GmbH, a solution provider and innovation leader in the pharmaceutical supply chain visibility, condition monitoring, and temperature-controlled packaging space. This strategic acquisition will strengthen Cryoport's condition monitoring systems and logistics management capabilities for the biopharmaceutical industry. Tec4med's technology and expertise will enhance Cryoport's end-to-end supply chain solutions and drive its digitization to provide customers with full transparency within the pharmaceutical supply chain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
acquisition
News
Cryoport to Report Third Quarter 2023 Financial Results on November 8, 2023
Rhea-AI Summary
Cryoport, a leading provider of products and services to the cell and gene therapy industry, will report Q3 2023 financial results on November 8, 2023. A document providing a review of Cryoport's performance will be issued along with the earnings release. A conference call for the investment community will be held on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
conferences earnings
-
News
Cryoport Inks New Multi-Year Supply Chain Solutions Agreement with Monash IVF
Rhea-AI Summary
Cryoport signs a 3-year supply chain solutions agreement with Monash IVF Group Limited.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
-
News
Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies
Rhea-AI Summary
Cryoport and CGT Catapult announce strategic partnership to support cell and gene therapies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
none
News
Be The Match BioTherapies® and Cryoport Partner to Accelerate the Development of Cell and Gene Therapies
Rhea-AI Summary
Be The Match BioTherapies and Cryoport announce strategic partnership to expand capabilities of IntegriCell solution for the global cell therapy market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
partnership
Stock CYRX logo
CryoPort Inc

Nasdaq:CYRX

CYRX Rankings

#2593 Ranked by Market Cap
#5071 Ranked by Stock Gains
N/A Ranked by Dividends

CYRX Stock Data

859.40M
44.46M
2.42%
107.67%
8.25%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Brentwood

About CYRX

cryoport delivers an innovative and complete outsourced frozen shipping solution for biological materials. this breakthrough combination replaces outdated dry ice shipping, virtually eliminates the risk of cell degradation and revolutionizes deep frozen logistics. we combine the technology of liquid nitrogen dry vapor shippers with the most advanced logistics management platform in the industry. when added with our logistics expertise, we provide a complete outsourced solution that advances deep-frozen shipping for the life science community. whether your business is bio-pharmaceuticals, clinical trials, research or reproductive medicine, you want to focus on your core mission. cryoport will help you transport life.